Patents by Inventor Kenneth S. Graham

Kenneth S. Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High Concentration VEGF Receptor Fusion Protein Containing Formulations
    Publication number: 20240058418
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: September 12, 2023
    Publication date: February 22, 2024
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • High Concentration VEGF Receptor Fusion Protein Containing Formulations
    Publication number: 20210353714
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 18, 2021
    Inventors: Kenneth S. Graham, Saurabh WADHWA
  • High concentration VEGF receptor fusion protein containing formulations
    Patent number: 11103552
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 31, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 11098127
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20210230283
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 8, 2021
    Publication date: July 29, 2021
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
    Patent number: 11071780
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 27, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. Vitti, Kristine A. Erickson, Karen W. Chu, Stanley J. Wiegand, Jingtai Cao, Ivan B. Lobov, Saurabh Wadhwa, Kenneth S. Graham, Daniel Dix
  • HIGH CONCENTRATION VEGF RECEPTOR FUSION PROTEIN CONTAINING FORMULATIONS
    Publication number: 20190343918
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Application
    Filed: May 10, 2019
    Publication date: November 14, 2019
    Inventors: Kenneth S. Graham, Saurabh Wadhawa
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20190117767
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 28, 2018
    Publication date: April 25, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20190002574
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 3, 2019
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 10072086
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 11, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20170080086
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20160144025
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: November 17, 2015
    Publication date: May 26, 2016
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20160002341
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 9173880
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: November 3, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • VEGF Antagonist Formulations for Intravitreal Administration
    Publication number: 20120087929
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence of residues 27-457 of SEQ ID NO:4.
    Type: Application
    Filed: December 19, 2011
    Publication date: April 12, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric FURFINE, Daniel Dix, Kenneth S. Graham, Kelly Frye
  • VEGF antagonist formulations for intravitreal administration
    Patent number: 8092803
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: January 10, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth S. Graham, Kelly Frye
  • VEGF ANTAGONIST FORMULATIONS FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20110257601
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
    Type: Application
    Filed: July 9, 2010
    Publication date: October 20, 2011
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth S. GRAHAM, Kelly FRYE
  • Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies
    Publication number: 20110171241
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 14, 2011
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. DIX, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Lyophilized VEGF antagonist formulations for intravitreal administration
    Patent number: 7807164
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: October 5, 2010
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth S. Graham, Kelly Frye
  • Lyophilized VEGF Antagonist Formulations for Intravitreal Administration
    Publication number: 20100075903
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
    Type: Application
    Filed: September 16, 2009
    Publication date: March 25, 2010
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric FURFINE, Daniel Dix, Kenneth S. Graham, Kelly Frye